Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2015 Oct 21:21:3186-96.
doi: 10.12659/msm.895257.

Common Polymorphisms in the NFKBIA Gene and Cancer Susceptibility: A Meta-Analysis

Affiliations
Meta-Analysis

Common Polymorphisms in the NFKBIA Gene and Cancer Susceptibility: A Meta-Analysis

Meng Zhang et al. Med Sci Monit. .

Abstract

Background: NFKBIA encodes the inhibitors of nuclear factor-κB (NF-κB), which regulate the translation of the genes involved in the inflammatory and immune reactions. Polymorphisms (rs2233406, rs3138053, and rs696) of NFKBIA have been implicated in susceptibility to many cancer types.

Material and methods: To evaluate the association between polymorphisms of NFKBIA and cancer susceptibility, a meta-analysis including a total of 7182 cancer cases and 10 057 controls from 28 case-control studies was performed. Data were extracted and pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated.

Results: Combined data demonstrated that rs3138053 polymorphism of NFKBIA was associated with cancer susceptibility in an allelic model (C vs. T: OR=10.754, 95%CI=4.175-27.697, Pheterogeneity=0.000), while the polymorphism of rs696 appeared to play a protective role in tumorigenesis (CC+CT vs. TT: OR=0.879, 95%CI=0.787-0.982, Pheterogeneity=0.107). When stratification analysis was performed by cancer type, an increased association of rs3138053 was recognized in hepatocarcinoma (C vs. T: OR=42.180, 95%CI=27.970-63.612, Pheterogeneity=0.007), while a decreased association of rs696 was identified in Hodgkin lymphoma (C vs. T: OR=0.792, 95%CI=0.656-0.956, Pheterogeneity=0.116; CC vs. TT: OR=0.658, 95%CI=0.448-0.965, Pheterogeneity=0.076; CC vs. CT+TT: OR=0.734, 95%CI=0.562-0.958, Pheterogeneity=0.347). By ethnicity, rs696 appears to be a protective candidate among Caucasians (CT vs. TT: OR=0.809, 95%CI=0.676-0.969, Pheterogeneity=0.459).

Conclusions: Our data demonstrated that the rs3138053 polymorphism of NFKBIA gene is a candidate for susceptibility to overall cancers, while rs696 plays a protective role.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow chart presenting the study selection procedure.
Figure 2A
Figure 2A
Meta-analysis of the association between NFKBIA rs3138053 polymorphism and overall cancer susceptibility (C vs. T).
Figure 2B
Figure 2B
Meta-analysis of the association between NFKBIA rs696 polymorphism and overall cancer susceptibility (CC+CT vs. TT).
Figure 2C
Figure 2C
Subgroup analysis of the association between NFKBIA polymorphisms and overall cancer risk by HWE (Hardy-Weinberg equilibrium).
Figure 3A
Figure 3A
Publication bias examinations by Begg’s funnel plots and Egger’s test (rs696: CC+CT vs. TT). Asymmetrical plots or P<0.10 suggest potential bias. Each point represents a separate study for the indicated association, and the horizontal line depicts mean effect size. Logor natural logarithm of OR; s.e. standard error.
Figure 3B
Figure 3B
Publication bias examinations by Begg’s funnel plots and Egger’s test (rs2233406: CC vs. CT+TT). Asymmetrical plots or P<0.10 suggest potential bias. Each point represents a separate study for the indicated association, and the horizontal line depicts mean effect size. Logor natural logarithm of OR; s.e. standard error.

Similar articles

Cited by

References

    1. Domingo-Domenech J, Oliva C, Rovira A, et al. Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity. Clin Cancer Res. 2006;12(18):5578–86. - PubMed
    1. Ahn KS, Sethi G, Aggarwal BB. Nuclear factor-kappa B: from clone to clinic. Curr Mol Med. 2007;7(7):619–37. - PubMed
    1. Naugler WE, Karin M. NF-kappaB and cancer-identifying targets and mechanisms. Curr Opin Genet Dev. 2008;18(1):19–26. - PMC - PubMed
    1. Lind DS, HS, Malaty J, Rekkas S, et al. Nuclear factor-kappa B is upregulated in colorectal cancer. Surgery. 2001;130:363–69. - PubMed
    1. Oltulu YM, Coskunpinar E, Ozkan G, et al. Investigation of NF-kappaB1 and NF-kappaBIA gene polymorphism in non-small cell lung cancer. Biomed Res Int. 2014;2014:530381. - PMC - PubMed

Publication types